This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer

This study has been terminated.
(Poor accrual)
Information provided by (Responsible Party):
Weill Medical College of Cornell University Identifier:
First received: February 16, 2012
Last updated: May 5, 2017
Last verified: May 2017
The purpose of this study is to look at the clinical benefit of carboplatin and paclitaxel and correlate response to study treatment with biologic parameters (i.e. lab studies of blood, urine, or tissue). It is hoped that this will allow researchers to gain insight into the underlying biology of prostate tumor progression and perhaps predict which patients may benefit from this chemotherapy regimen.

Condition Intervention Phase
Prostate Cancer Drug: Carboplatin Drug: Paclitaxel Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer Previously Treated With Docetaxel

Resource links provided by NLM:

Further study details as provided by Weill Medical College of Cornell University:

Primary Outcome Measures:
  • Change in Prostate-specific Antigen (PSA) Level [ Time Frame: Baseline, week 4, week 8, week 12, week 16, week 20, week 24 and end of study. ]
  • Change in Tumor Size [ Time Frame: Baseline, week 12, week 24 and end of study. ]
    Assessed by CT or MRI scan and/or bone scan.

Secondary Outcome Measures:
  • Change in Survival Status [ Time Frame: 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months and 48 months. ]

Enrollment: 3
Actual Study Start Date: March 2011
Study Completion Date: November 2013
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: All subjects
Carboplatin and Paclitaxel
Drug: Carboplatin
AUC = 5 intravenously (IV) on day 1 of a 28 day cycle
Other Name: Paraplatin
Drug: Paclitaxel
80 mg/m2 intravenously (IV) weekly on days 1, 8, and 15 of a 28 day cycle
Other Name: Taxol

Detailed Description:
Docetaxel/prednisone is the standard of care in patients with metastatic, castrate-resistant prostate cancer (CRPC) but duration of response is limited, with median time to prostate-specific antigen (PSA) progression of 6-8 months. There is currently no standard second-line therapy for patients who have progressed after receiving docetaxel. Carboplatin and paclitaxel have demonstrated activity, but prospective clinical trials evaluating this regimen are limited. In addition, correlative studies investigating why some patients respond are lacking.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologic or cytologic diagnosis of prostate carcinoma.
  • Subject must have progressive metastatic prostate cancer despite adequate medical or surgical castration therapy. Furthermore, if applicable, medical castration must be maintained for the duration of the protocol.
  • Serum testosterone < 50 ng/ml.
  • Subjects who have received anti-androgen therapy with a resulting PSA decline must demonstrate progression following discontinuation of anti-androgen therapy.
  • Subjects capable of fathering children must agree to use an effective method of contraception for the duration of the trial.
  • Must have previously received docetaxel for prostate cancer
  • ECOG performance status 0-2
  • Willing and able to give informed consent

Exclusion Criteria:

  • Platelet count <100,000/mm3
  • Absolute neutrophil count (ANC) <1,500/mm3
  • Hemoglobin < 8 g/dL
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 x upper limit of normal
  • Bilirubin (total) >2 x upper limit of normal. Subjects with known Gilbert's syndrome are eligible if direct bilirubin is within normal limits
  • For subjects with serum creatinine > 1.5 x ULN, calculated creatinine clearance < 30 ml/min are excluded; subjects meeting this exclusion criterion are eligible if a measured clearance is > 30 ml/min
  • Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study
  • Prior investigational therapy within 4 weeks of treatment. Furthermore, other investigational anti-cancer therapy is not permitted during the treatment phase.
  • Grade > 1 peripheral neuropathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01558492

United States, New York
Weill Cornell Medical College
New York, New York, United States, 10021
Sponsors and Collaborators
Weill Medical College of Cornell University
Principal Investigator: Himisha Beltran, M.D. Weill Medical College of Cornell University
  More Information

Responsible Party: Weill Medical College of Cornell University Identifier: NCT01558492     History of Changes
Other Study ID Numbers: 1008011188
Study First Received: February 16, 2012
Results First Received: February 28, 2017
Last Updated: May 5, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Weill Medical College of Cornell University:
Metastatic Castrate Resistant Prostate Cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017